The estimated Net Worth of Eyal Talor is at least $2.92 Миллион dollars as of 19 October 2021. Eyal Talor owns over 15,000 units of Cel-Sci stock worth over $123,781 and over the last 21 years he sold CVM stock worth over $564,343. In addition, he makes $2,232,220 as Chief Scientific Officer at Cel-Sci.
Eyal has made over 16 trades of the Cel-Sci stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of CVM stock worth $168,750 on 19 October 2021.
The largest trade he's ever made was selling 100,000 units of Cel-Sci stock on 5 June 2009 worth over $58,000. On average, Eyal trades about 3,678 units every 50 days since 2003. As of 19 October 2021 he still owns at least 104,899 units of Cel-Sci stock.
You can see the complete history of Eyal Talor stock trades at the bottom of the page.
Dr. Eyal Talor Ph.D. serves as Chief Scientific Officer of the Company. Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 25 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III, in the biopharmaceutical industry. His expertise includes; biopharmaceutical R&D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I – III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&D and Clinical Development at CBL, Inc., Principal Scientist - Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine’s composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells (‘Adapt’) and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation reject
As the Chief Scientific Officer of Cel-Sci, the total compensation of Eyal Talor at Cel-Sci is $2,232,220. There are 2 executives at Cel-Sci getting paid more, with Geert Kersten having the highest compensation of $4,546,360.
Eyal Talor is 64, he's been the Chief Scientific Officer of Cel-Sci since 2009. There are 9 older and 4 younger executives at Cel-Sci. The oldest executive at Cel-Sci Corp. is Dr. Daniel H. Zimmerman Ph.D., 80, who is the Sr. VP of Research & Cellular Immunology.
Eyal's mailing address filed with the SEC is 8229 BOONE BLVD, STE 802, VIENNA, VA, 22182.
Over the last 21 years, insiders at Cel-Sci have traded over $3,069,559 worth of Cel-Sci stock and bought 1,693,350 units worth $1,328,136 . The most active insiders traders include Clara Maximilian De, Geert R Kersten и Eyal Talor. On average, Cel-Sci executives and independent directors trade stock every 50 days with the average trade being worth of $42,938. The most recent stock trade was executed by Robert Eugene Watson on 8 May 2024, trading 20,000 units of CVM stock currently worth $27,800.
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
Cel-Sci executives and other stock owners filed with the SEC include: